COVID-19 Bivalent Booster Shot Q&A for Clinicians

The US Food and Drug Administration recently amended the emergency use authorizations of the Moderna and Pfizer-BioNTech COVID-19 vaccines to authorize single booster doses of bivalent formulations targeting the BA.4 and BA.5 omicron variants of the SARS-CoV-2 virus. With bivalent booster doses now available, clinicians may have questions about updated vaccination guidance. To provide answers for busy clinicians, the Centers for Disease Control and Prevention updated its Interim Clinical Considerations for COVID-19 Vaccination page to include information on bivalent booster doses. Below, 7 questions you may have when considering administering bivalent booster doses in your practice and answers to help.